Iondrive Reports 93.5% Dysprosium Recovery From US E-Waste Validation

Technical progress, but commercial value is still distant and unproven for ASX:ION investors.

What the company is saying

Iondrive is telling investors that its IONSolv process has achieved a major technical breakthrough in rare-earth recovery from commercial US e-waste, with independent test work showing much higher recovery rates than previously assumed. The company specifically highlights a 93.5% dysprosium recovery, which is nearly triple the 32.5% figure used in its November 2025 techno-economic analysis (TEA), and 96.5% recoveries for both neodymium and praseodymium, all of which are above prior assumptions. The announcement frames these results as 'materially strengthening' the business case for IONSolv, using language that suggests a step-change in project economics is likely once these numbers are incorporated into a refreshed study. Iondrive emphasizes the independent nature of the test work and the improved process selectivity, including 99.9% iron rejection, to bolster credibility. However, the company is careful to note that these are unaudited leach efficiencies, not yet confirmed by full mass-balance, and that further validation is required. The announcement is forward-looking, focusing on plans for a TEA refresh and a pre-feasibility study (PFS) once feedstock supply assumptions are secured, but it does not provide a timeline for commercial production or a final investment decision. There is no mention of revenue, profit, or binding commercial agreements, and the company buries the fact that the economic impact of these technical results is still unquantified. The tone is confident and optimistic, projecting technical competence and strategic vision, but it stops short of making hard financial promises. No notable individuals are named, so there is no added institutional credibility or risk from high-profile backers. This narrative fits Iondrive's broader strategy of positioning itself as a technology-driven rare earths recovery play, but the messaging remains aspirational and contingent on future milestones.

What the data suggests

The disclosed numbers show that Iondrive's latest independent test work achieved 93.5% dysprosium recovery, a substantial increase from the 32.5% assumption in the November 2025 TEA. Neodymium and praseodymium recoveries are reported at 96.5% each, both slightly above the prior TEA assumptions of 95.5% and 92%, respectively. The company also cites 99.9% iron rejection, indicating strong process selectivity. However, these recovery rates are unaudited and represent leach efficiencies, not full process yields, and have not been validated by mass-balance or at commercial scale. The only financial data provided are from the previous TEA: a 2,000 tonnes per annum modular plant with US$4.6 million capex, US$7 million NPV (at a 10% real discount rate), 46% IRR, and a 2.6-year payback. There is no updated TEA or PFS incorporating the new recovery rates, so the actual financial impact remains unknown. No revenue, profit, or cash flow figures are disclosed, and there is no period-over-period comparison or evidence of commercial progress. The quality of technical disclosure is high, but the financial disclosure is incomplete and outdated, making it impossible to independently assess the project's current economic viability. An analyst looking only at the numbers would conclude that while the technical results are promising, the lack of updated economics, commercial agreements, or operational data means the investment case is still speculative.

Analysis

The announcement uses positive language to highlight improved rare-earth recovery rates from independent test work, but the majority of realised claims are technical (recovery percentages) rather than commercial or financial milestones. While the new dysprosium result is a significant technical improvement over prior assumptions, the benefits are not yet realised at commercial scale, and the results are unaudited and not confirmed by full mass-balance. Most forward-looking statements concern future studies (TEA refresh, PFS) and depend on further validation and feedstock certainty, with no timeline for commercialisation. The only disclosed capital outlay is from a previous TEA (US$4.6 million capex), and there is no evidence of committed funding or immediate earnings impact. The narrative inflates the signal by implying that technical test work alone 'materially strengthens' the business case, without updated economics or binding commercial progress.

Risk flags

• ●The majority of claims are forward-looking, with key milestones such as a TEA refresh and PFS still pending. This means investors are being asked to buy into a vision rather than a proven business, increasing the risk of delays or non-delivery.
• ●Capital intensity is flagged by the previous TEA's US$4.6 million capex for a single modular plant, and the company references staged capital deployment. High upfront costs with distant payoff are a classic risk in resource processing projects, especially when funding is not yet secured.
• ●Operational risk is significant because the reported recovery rates are unaudited leach efficiencies, not full process yields. There is no evidence these results can be replicated at scale or in a commercial setting, and scale-up failures are common in process industries.
• ●Disclosure risk is present: while technical data is detailed, financial disclosure is limited to outdated TEA figures. There is no updated NPV, IRR, or payback incorporating the new recovery rates, making it impossible to assess current project economics.
• ●Execution risk is high, as the company must still secure feedstock supply, validate process performance at scale, and complete further studies before any commercial decision. Each of these steps introduces potential for slippage or underperformance.
• ●Timeline risk is acute: with no timeline for commercial production or even for the next study, investors face a long wait before any value realisation. Projects at this stage often experience delays, and the lack of a clear schedule compounds uncertainty.
• ●Pattern-based risk is evident in the company's emphasis on technical milestones without corresponding commercial progress. This can be a red flag if repeated over multiple announcements, as it may signal difficulty in moving from lab to market.
• ●No notable individuals or institutional backers are named, so there is neither the credibility boost nor the risk of over-reliance on a single champion. However, the absence of such support also means there is no external validation of the business case.

Bottom line

For investors, this announcement means Iondrive has achieved a technical milestone in rare-earth recovery, but the commercial implications are still entirely theoretical. The company has demonstrated strong recovery rates for dysprosium, neodymium, and praseodymium in independent test work, but these results are unaudited and not yet validated at scale or in a commercial context. The narrative is credible as a technical update, but lacks the financial and operational substance needed to support an investment decision. No notable institutional figures are involved, so there is no external validation or implied deal flow. To change this assessment, the company would need to disclose updated economic analysis (NPV, IRR, payback) that incorporates the new recovery rates, evidence of binding feedstock agreements, and a clear timeline for moving from study to commercial operation. Investors should watch for the next reporting period to see if a refreshed TEA or PFS is delivered, whether feedstock supply is secured, and if any commercial or funding agreements are announced. At this stage, the information is worth monitoring but not acting on, as the signal is technical rather than commercial. The single most important takeaway is that while the technical results are promising, the path to commercial value is long, uncertain, and unproven—investors should not mistake lab success for investable progress.

Announcement summary

(ASX: ION) Iondrive reported that independent test work on commercial US e-waste has materially strengthened the rare-earth recovery case for its IONSolv process, with 93.5% dysprosium recovery and 96.5% recoveries for both neodymium and praseodymium. The new dysprosium result of 93.5% is significantly higher than the 32.5% recovery assumption used in the company's November 2025 techno-economic analysis (TEA). The previous TEA was based on a 2,000 tonnes per annum modular plant, with US$4.6 million in capex, an NPV of US$7 million at a 10% real discount rate, an IRR of 46%, and a payback of 2.6 years. The filing also referenced 99.9% iron rejection and noted that the recoveries are unaudited leach efficiencies, not yet confirmed by full mass-balance results. In April 2026, Iondrive disclosed third-party test work on magnet recycling feedstock, with 93.8% neodymium and 95.1% praseodymium extraction from a 250kg bulk sample. The company plans a TEA refresh through a pre-feasibility study (PFS) once feedstock supply assumptions are firmed up. Iondrive's broader strategy involves a phased hub-and-spoke deployment model with modular plants processing targeted feedstock streams and supporting staged capital deployment.

Disagree with this article?